ClinicalTrials.gg
Not yet recruitingNCT07667296Updated Jul 1, 2026

APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of APG-157 and Surgery in Head and Neck Cancer, Head and Neck (HNSCC) and Oropharyngeal, sponsored by Aveta Biomics, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's listed conditions name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aveta Biomics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
826
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy after chemoradiotherapy in participants with unresectable or medically inoperable disease. Participants are randomized 1:1 within each cohort to receive APG-157-based treatment or standard-of-care therapy. The primary hypothesis is that APG-157 given before definitive surgery followed by (chemo)radiotherapy improves event-free survival (EFS) compared to surgery and adjuvant (chemo)radiotherapy alone (Cohort A), and that APG-157 given as induction therapy prior to definitive chemoradiotherapy (CRT) followed by maintenance APG-157 improves EFS compared to definitive CRT alone (Cohort B).

Read the detailed description

This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The study consists of two independently powered cohorts designed to evaluate APG-157 in distinct treatment settings. Cohort A enrolls participants with resectable oral cavity or oropharyngeal squamous cell carcinoma who are objectively medically ineligible for perioperative pembrolizumab according to protocol-defined criteria. Participants are randomized 1:1 to receive APG-157 administered orally at 600 mg/day for 6 weeks prior to curative-intent surgical resection followed by protocol-directed adjuvant therapy, or standard-of-care surgery followed by adjuvant therapy alone. Cohort B enrolls participants with unresectable or medically inoperable locally advanced oropharyngeal squamous cell carcinoma. Participants are randomized 1:1 to receive APG-157 induction therapy for 4 weeks before definitive chemoradiotherapy, followed by APG-157 maintenance therapy initiated within 60 days after chemoradiotherapy and continued for up to 1 year, or standard-of-care definitive chemoradiotherapy alone.The primary objective is to determine whether APG-157-based treatment improves event-free survival compared with standard-of-care treatment. Key secondary objectives include overall survival, objective response, pathological response, ctDNA clearance, safety, treatment feasibility, and patient-reported outcomes.

02

Conditions studied

  • Head and Neck Cancer
  • Head and Neck (HNSCC)
  • Oropharyngeal
  • Oral Cavity
  • Oral Cavity Carcinoma
  • Oropharynx Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma
03

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

This study's planned enrollment of 826 is above the median of 48 across 1,654 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Aveta Biomics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort A (Resectable Disease)

  1. Adults ≥18 years
  2. or cytologically confirmed, previously untreated locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity or oropharynx.
  3. Resectable disease appropriate for curative-intent surgery.
  4. Stage III-IVA disease according to AJCC criteria:

    • Oropharynx, p16-positive: Stage III (T4, N0-N3, M0)
    • Oropharynx, p16-negative: Stage III or IVa (T3-T4, N0-N2, M0)
    • Oral cavity: Stage III or IVa (T3-T4, N0-N2, M0)
  5. Objectively medically ineligible for perioperative pembrolizumab according to protocol-defined objective criteria.
  6. HPV/p16 testing available for stratification.
  7. Measurable or evaluable disease.
  8. ≥12 months.
  9. Performance Status ≤2.
  10. Negative pregnancy test for women of and agreement to use effective .
  11. Ability to comply with study procedures.

Cohort B (Unresectable / Medically Inoperable Disease)

  1. Adults ≥18 years
  2. Histologically or cytologically confirmed, previously untreated LA-HNSCC of the oropharynx. Disease not suitable for curative-intent surgery.
  3. Stage III-IVA disease according to AJCC criteria:

    • p16-positive Stage III (T4, N0-N3, M0) with >10 pack-year smoking history
    • p16-negative Stage III or IVa (T3-T4, N0-N2, M0)
  4. HPV/p16 testing available for stratification.
  5. Presence of evaluable tumor burden.
  6. Eligible to receive definitive chemoradiotherapy.
  7. Life expectancy ≥12 months.
  8. ECOG Performance Status ≤2.
  9. Adequate organ function.
  10. Contraception requirements met.
  11. Ability to comply with study procedures.

Exclusion criteria

Exclusion Criteria

Cohort A Specific:

  • Stage I-II disease
  • Stage IVb or Ivc disease
  • T4b unresectable disease
  • N3 disease where applicable
  • Medically eligible for perioperative pembrolizumab

Cohort B Specific:

  • Stage I-II disease
  • Disease not appropriate for curative-intent CRT
  • Active disease requiring systemic therapy
  • Prior solid organ or stem cell transplant
  • Ongoing >10 mg/day prednisone equivalent

Common Exclusion Criteria:

  • Primary tumor arising from the nasopharynx, hypopharynx, larynx, paranasal sinus, or unknown primary site.
  • Prior treatment for current head and neck squamous cell carcinoma.
  • Prior unless protocol exceptions met
  • Distant disease
  • within 30 days
  • Known to APG-157 or its components.
  • Unresolved toxicity
  • Recent participation in another study
  • Active uncontrolled infection
  • Significant uncontrolled cardiovascular disease
  • Pregnancy or breastfeeding.
  • >500 msec or congenital long QT syndrome
  • Any condition compromising safety, compliance, or study interpretation

Randomization ratio: 1:1 within each cohort

Stratification Factors:

Cohort A:

  • HPV/p16 status,
  • Planned platinum strategy,
  • CPS category

Cohort B:

  • HPV/p16 status
  • Planned platinum strategy
  • Geographic region.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
826 participants (estimated)

Study arms

  • Experimental
    Cohort A - APG-157

    APG-157 600 mg/day (200 mg orally three times daily)for 6 weeks prior to curative-intent surgery followed by protocol-directed adjuvant therapy.

    Drug: APG-157 · Procedure: Surgery · Radiation: Radiation/Chemotherapy

  • Active comparator
    Cohort A - Control

    Standard-of-care surgery and adjuvant therapy; Participants undergo curative-intent surgery followed by protocol-directed adjuvant therapy

    Procedure: Surgery · Radiation: Radiation/Chemotherapy

  • Experimental
    Cohort B - APG-157

    APG-157 induction therapy and standard-of-care definitive chemoradiotherapy followed by APG-157 maintenance therapy. Participants receive APG-157 600 mg/day for 4 weeks (200 mg orally three times daily) prior to definitive chemoradiotherapy, followed by APG-157 maintenance therapy for up to 1 year

    Drug: APG-157 · Radiation: Radiation/Chemotherapy

  • Active comparator
    Cohort B - Control

    Standard-of-Care Chemoradiotherapy. Participants receive definitive upfront chemoradiotherapy

    Radiation: Radiation/Chemotherapy

Interventions

  • APG-157 is a first-in-class investigational drug product, formulated as 100 mg soft hydrogel pastille to dissolve in the mouth

  • ProcedureSurgery

    Definitive Surgery

  • RadiationRadiation/Chemotherapy

    Protocol-specified risk-adapted postoperative radiotherapy, with concurrent platinum-based chemotherapy (e.g., cisplatin or carboplatin) administered when indicated based on pathological risk factors

  • RadiationRadiation/Chemotherapy

    Definitive radiotherapy with concurrent protocol-specified platinum-based chemotherapy.

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to the earliest occurrence of a protocol-defined EFS event, including radiographic and/or clinical disease progression that precludes initiation or completion of planned definitive curative-intent therapy; locoregional recurrence, progression, or distant metastasis following definitive treatment, confirmed by imaging, pathology, salvage intervention with viable tumor or other protocol-defined assessments, where applicable, or death from any cause. EFS will be analyzed by blinded independent central review (BICR) using RECIST v1.1 and protocol-defined pathology criteria, as applicable. The primary analysis will be conducted in the intent-to-Treat ( ITT) population using stratified log-rank testing and Cox proportional hazards models.

    Time frame: From randomization until the first occurrence of a protocol-defined EFS event, death, withdrawal from study follow-up, or study completion, assessed for up to approximately 36 months.

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization until death from any cause.

    Time frame: Time from randomization until death from any cause; assessed up to approximately 60 months.

  2. Objective Response Rate (ORR)

    Proportion of participants achieving confirmed response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR.

    Time frame: • Cohort A: Week 6 and pre-surgery assessment • Cohort B: Week 4 and pre-CRT assessment

  3. ctDNA Clearance Rate

    Change in circulating tumor DNA (ctDNA) levels over time and proportion of participants achieving ctDNA clearance from the baseline assessed using a tumor-informed assay.

    Time frame: Baseline through protocol-defined follow-up assessments up to approximately 36 months.

  4. Clinically Meaningful Pathological Response(Cohort A):

    Proportion of participants achieving ≤50% residual viable tumor in the resected specimen as assessed by BICR.

    Time frame: At definitive surgery (approximately 6-9 weeks after randomization).

  5. Major Pathologic Response (MPR) (Cohort A)

    Proportion of participants achieving ≤10% residual viable tumor in the resected specimen as assessed by BICR.

    Time frame: At definitive surgery.

  6. Composite Pathologic Response (Cohort A)

    Composite assessment including: * Pathologic tumor response category * Surgical margin status * Extranodal extension status * Clinical-to-pathologic downstaging

    Time frame: At definitive surgery.

  7. Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Treatment Discontinuations Due to Adverse Events

    Time frame: From first dose through 30 days after last study treatment.

  8. Patient-Reported Outcomes

    EuroQol-5 Dimension, 5-Level (EQ-5D-5L). Change from baseline in the EQ-5D-5L Health Utility Index score. The Health Utility Index is derived from responses to the five EQ-5D-5L dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a country-specific value set. Scores typically range from less than 0 (health states considered worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life.

    Time frame: Baseline through approximately 36 months.

  9. Patient-Report Outcomes

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30). Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale score. The Global Health Status/Quality of Life Scale is transformed to a 0 to 100 scale, with higher scores indicating better global health status and quality of life.

    Time frame: Baseline through approximately 36 months

  10. Ability to Initiate Definitive Therapy

    Proportion of participants able to initiate protocol-defined definitive curative-intent therapy within protocol-specified timing windows (Within 21 days after the last dose of APG-157 prior to definitive surgery (Cohort A) or definitive chemoradiotherapy (Cohort B))

    Time frame: Up to 21 days after last dose of APG-157

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The sponsor does not currently plan to make individual participant data available to researchers outside the study sponsor and its designated representatives. Study results will be made publicly available through ClinicalTrials.gov and scientific publications as appropriate.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2031, 65 months later.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 65 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 25, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2032
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07667296
Lead sponsor
Aveta Biomics, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jul 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Curcumin/Polyphenols-containing Botanical Agent APG-157

Start the discussion